Ipsen
Ipsen
-0,35 %
113,10 EUR
-0,40
Kurs
113,10
Hög
115,60
Förändring
-0,35 %
Låg
112,60
Uppdaterad
2019-07-19
Öppen
114,00
Factsheet for Ipsen
Company Profile
Description
Ipsen SA is a specialty and generic drug manufacturing company. The company's main therapeutic areas include oncology, endocrinology, neurosciences, and primary care. Ipsen maintains two segments: specialty care and primary care. The company derives most of its sales from the specialty care segment, with a vast majority of sales being generated in Western European countries. Ipsen's research and development strategy focuses on peptides and toxins. The company considers merger and acquisition investment as a potential component of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.
Key Stats
Website: http://www.ipsen.com
Headquarter country: France
Employees: 4 602
Market Cap (at close 19-07-2019): EUR 9B
Fiscal Year Ends: december
Stats

Stats 2018 2017 2016 2015 2014
Price/Earnings 27,30 38,00 24,40 36,10 22,80
Forward Price/Earnings 15,90 21,50 17,90 17,60 19,40
Price/Free Cash Flow 33,50 158,70 159,10 34,50 31,20
Return on Assets 12,10 9,90 10,40 10,40 9,40
Return on Equity 23,10 18,90 17,50 16,60 15,10
Return on Invested Capital 19,40 15,80 14,40 16,60 15,30
Dividend


Dividend/Share:1,00
Ex. Dividend Date:2018-12-31
Trailing Dividend Yield:0,88
Payout Ratio:21,51
Date Currency Amount
Income Statement

Revenue 2018 2017 2016 2015 2014
Total Revenue 2 348,40 2 011,70 1 671,10 1 520,20 1 332,40
Gross Profit 1,89 1,63 1,32 1,18 1,02
Gross Margin % 80,66% 80,83% 78,86% 77,85% 76,73%
Operating Expenses 2018 2017 2016 2015 2014
EBITDA 647,00 488,00 344,00 285,00 262,00
Net income 390,00 272,00 226,00 190,00 154,00
Basic Earnings Per Share 4,70 3,30 2,74 2,31 1,87
Operating Income 0,56 0,40 0,35 0,32 0,25
Operating Margin % 23,69% 19,94% 20,91% 20,73% 18,86%
Cash Flow

Cash Flow 2018 2017 2016 2015 2014
Operating Cash Flow 571,00 423,00 318,00 224,00 246,00
Capital Expenditures -288,00 -241,00 -372,00 -75,00 -84,00
Free Cash Flow 283,00 182,00 -55,00 148,00 161,00
Balance Sheet

Assets 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Current Assets 1 185,60 1 016,40 1 050,40 809,90 671,60 601,85
Long Term Assets 2 191,80 2 055,60 1 373,10 1 128,10 1 041,70 963,49
Total Assets 3 377,40 3 072,00 2 423,50 1 938,00 1 713,30 1 565,33
Liabilities 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Total Current Liabilities 959,20 941,80 561,30 461,50 410,20 376,24
Long Term Liabilities 503,30 254,00
Total Liabilities 1 064,60 715,50
Equity 2018-12-31 2017-12-31 2016-12-31 2015-12-31 2014-12-31
Retained Earnings 389,50 272,30 225,90 189,90 153,50 152,54
Treasury Stock
Total Stockholder Equity 1 841,10 1 525,40 1 358,90 1 222,50 1 065,20 971,50
Net Tangible Assets 433,50 206,20 621,70 717,90 580,00 515,99